Yahoo Web Search

  1. IMMITICIDE for Animal Use -

    Sep 02, 2020 · The signs exhibited by these dogs, in addition to the signs described above, included collapse, severe salivation, vomiting, respiratory distress, cyanosis, stupor, and death within 4 hours of the first dose in two dogs and within 20 hours of the second dose in one dog.

  2. PetAction CapAction for Animal Use -
    • Active Ingredients
    • Directions
    • Dosage
    • Adverse Reactions
    • Other Information
    • Flea Infestations on Dogs and Cats

    CAPACTION™ Tablets contain 11.4 or 57.0 mg of nitenpyram, which belongs to the chemical class of neonicotinoids. Nitenpyram kills adult fleas.

    CAPACTION™ Tablets kill adult fleas and are indicated for the treatment of flea infestations on dogs, puppies, cats and kittens 2 pounds of body weight or greater and 4 weeks of age and older. A single dose of CAPACTION™ should kill the adult fleas on your pet. If your pet gets re-infested with fleas, you can safely give another dose as often as once per day. To give CAPACTION™ Tablets, place the pill directly in your pet’s mouth or hide it in food. If you hide the pill in food, watch closely to make sure your pet swallows the pill. If you are not sure that your pet swallowed the pill, it is safe to give a second pill. Treat all infested pets in the household. Fleas can reproduce on untreated pets and allow infestations to persist.

    CAPACTION™ Tablets should be administered according to the following schedule. Weigh your pet prior to administration to ensure proper dosage. Do not administer to pets under 2 pounds.

    Pre-approval laboratory and clinical studies showed that CAPACTION™ Tablets are safe for use in dogs and cats, puppies and kittens 2 pounds of body weight or greater and 4 weeks of age and older. (See Post-Approval Experience section). Post-Approval Experience (Rev. 2011): The following adverse events are based on post-approval adverse drug experience reporting. Not all adverse reactions are reported to FDA CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using this data. The following adverse events are listed in decreasing order of reporting frequency. CATS:hyperactivity, panting, lethargy, itching, vocalization, vomiting, fever, decreased appetite, nervousness, diarrhea, difficulty breathing, salivation, incoordination, seizures, pupil dilation, increased heart rate, and trembling. DOGS:lethargy/depression, vomiting, itching, decreased appetite, diarrhea, hyperactivity, incoordination, trembling...

    CAPACTION™ Tablets begin working within 30 minutes. In studies, CAPACTION™ achieved greater than 90% effectiveness against adult fleas on dogs within 4 hours and cats within 6 hours. CAPACTION™ Tablets are safe for pregnant or nursing dogs and cats (See Post-Approval Experience section). When using this product, you may notice that your dog or cat will start scratching itself as fleas begin to die. The scratching behavior is temporary and is a reaction to the fleas, not the drug. In cats and dogs, this may present as transient signs of hyperactivity, panting, vocalization and excessive grooming/licking. CAPACTION™ Tablets kill adult fleas that cause flea allergy dermatitis (FAD). CAPACTION™ Tablets may be used together with other products, including heartworm preventives, corticosteroids, antibiotics, vaccines, de-worming medications, shampoos and other flea products.

    In addition to the common nuisance irritations associated with infestations, fleas can be responsible for skin conditions in your pet such as flea allergy dermatitis (FAD) in the dog and miliary dermatitis in the cat. Also, fleas transmit other parasites, including tapeworms. The control of flea infestations is important to your pet’s health and also reduces the problems associated with these parasites. CAPACTION™ Tablets do not have an effect on fleas in the pet’s environment. You may need to treat more than one time because immature fleas in and around the home will continue to develop into adults that can reinfest your pet. The following diagram illustrates the flea’s life cycle and where CAPACTION™ Tablets work:

  3. EFFITIX Topical Solution for Dogs for Animal Use -

    Sep 02, 2020 · Fleas: EFFITIX ® Topical Solution for Dogs can start killing adult fleas within 6 hours and lasts for up to three months. Apply monthly if your dog has fleas that may cause flea allergy dermatitis (FAD), or if re-infestation is likely. Ticks: EFFITIX ® Topical Solution for Dogs can kill ticks for at least a month. Apply monthly where tick ...

  4. People also ask

    What are the side effects of a cough?

    What are the symptoms of a fever?

    What is the treatment for heartworm in dogs?

    What is the dose of lumbar dosing for dogs?

  5. ProHeart 12 for Animal Use -
    • Description
    • Proheart 12 Indications
    • Proheart 12 Dosage and Administration
    • Contraindications
    • Human Warnings
    • Warnings
    • Precautions
    • Adverse Reactions
    • Information For Dog Owners
    • Clinical Pharmacology

    ProHeart 12 (moxidectin) for extended-release injectable suspension consists of two separate vials: one vial contains 10% moxidectin sterile microspheres; and the second vial contains a specifically formulated sterile vehicle for constitution with the microspheres. A clear or translucent appearance of the vehicle is normal. Each mL of constituted drug product contains 10 mg moxidectin, 9% glyceryl tristearate, 2.25% hydroxypropyl methylcellulose, 0.81% sodium chloride, 0.16% methylparaben, 0.02% propylparaben and 0.004% butylated hydroxytoluene. Hydrochloric acid is used to adjust pH. The constituted product may appear as a hazy to milky suspension.

    ProHeart 12 is indicated for use in dogs 12 months of age and older for the prevention of heartworm disease caused by Dirofilaria immitisfor 12 months. ProHeart 12 is indicated for the treatment of existing larval and adult hookworm (Ancylostoma caninum and Uncinaria stenocephala)infections.

    Always provide Client Information Sheet and review with owners before administering ProHeart 12. The owner should be advised to observe their dog for adverse drug events including those described on the sheet. The Client Information Sheet is attached to this package insert and available online at for reprinting to provide to the owner. Frequency of Treatment: ProHeart 12 prevents the development of heartworm disease caused by D. immitisfor 12 months. For dogs not previously on heartworm preventive or having lapsed beyond 12 months of a prior ProHeart 12 dose, the product should be given within 1 month of exposure to mosquitoes. Follow-up treatments may be given every 12 months, if the dog continues to be healthy and without weight loss, to provide continuous year-round protection. When replacing a monthly heartworm preventive product, ProHeart 12 should be given within one month of the last dose of the former medication to avoid a gap in protection. ProHear...

    ProHeart 12 is contraindicated in animals previously found to be hypersensitive to this drug or ProHeart 6.

    Not for human use. Keep this and all drugs out of the reach of children. If contact with your skin occurs, wash thoroughly with water. May be irritating to the eyes. If product accidentally gets into your eyes, flush eyes thoroughly with water. In case of accidental ingestion, or if skin or eye irritation occurs, contact a Poison Control Center or physician for treatment advice and show the package insert to the physician. Take care to avoid accidental self-injection. In case of accidental self-injection, seek medical advice and show the package insert or the label to the physician. The Safety Data Sheet (SDS) contains more detailed occupational safety information.

    Anaphylactic and anaphylactoid reactions may occur in some dogs following administration of ProHeart 12 alone or with vaccines. In some cases, these reactions have resulted in death following administration of moxidectin microspheres (see POST-APPROVAL EXPERIENCE). Anaphylactic and anaphylactoid reactions should be treated immediately with the same measures used to treat hypersensitivity reactions to vaccines and other injectable products. Always provide Client Information Sheet and review with owners before administering ProHeart 12. The owner should be advised to observe their dog for adverse drug events including those described on the sheet. Do not administer ProHeart 12 to dogs who are sick, debilitated, underweight or who have a history of weight loss.

    Prior to administration of ProHeart 12, the health of the patient should be assessed by a thorough medical history, physical examination and diagnostic testing as indicated (see WARNINGS). Caution should be used when administering ProHeart 12 in dogs with pre-existing allergic disease, including food allergy, atopy, and flea allergy dermatitis. (see WARNINGS). Caution should be used when administering ProHeart 12 concurrently with vaccinations. Adverse reactions, including anaphylaxis, have been reported following the concomitant use of moxidectin microspheres and vaccinations (see WARNINGS and POST-APPROVAL EXPERIENCE). ProHeart 12 should not be used more frequently than every 12 months. The effectiveness of ProHeart 12 has not been evaluated in dogs less than 12 months of age. Prior to administration of ProHeart 12, dogs should be tested for existing heartworm infections. Infected dogs should be treated with an adulticide to remove adult heartworms. ProHeart 12 is not effective ag...

    A well-controlled field study was conducted, including a total of 593 dogs (297 received two doses of ProHeart 12, 12 months apart and 296 received a monthly oral heartworm preventive as active control) ranging in age from 1 to 14 years. Over the 605-day study period, all observations of potential adverse reactions were recorded. Table 2: Number of Dogs* with Adverse Reactions Reported During the ProHeart 12 Field Study *Some dogs may have experienced more than one adverse reaction or more than one occurrence of the same adverse reaction during the study. Two ProHeart 12 (moxidectin) - treated dogs experienced anaphylactoid/hypersensitivity-related clinical signs within the first 24 hours following the initial treatment. Both dogs responded to symptomatic treatment. One dog experienced hives and facial swelling that resolved in 24 hours. The second dog experienced redness and swelling of the face and paws, followed by vomiting, polydipsia, and elevated heart rate and was treated sym...

    Always provide Client Information Sheet and review with owners before administering ProHeart 12. Owners should be advised of the potential for adverse reactions, including anaphylaxis, and be informed of the clinical signs associated with drug toxicity (see WARNINGS, ADVERSE REACTIONS and POST-APPROVAL EXPERIENCEsections.) Owners should be advised to contact their veterinarian immediately if signs of toxicity are observed. The vast majority of patients with drug related adverse reactions have recovered when the signs are recognized and veterinary care, if appropriate, is initiated.

    Moxidectin is a semi-synthetic methoxime derivative of nemadectin which is a fermentation product of Streptomyces cyaneogriseus subspecies noncyanogenus. Moxidectin is a pentacyclic 16-membered lactone macrolide. Moxidectin has activity resulting in paralysis and death of affected parasites. The stage of the canine heartworm affected at the recommended dose rate of 0.5 mg/kg (0.23 mg/lb) is the tissue larval stage. The larval and adult stages of the canine hookworms, A. caninum and U. stenocephala, are susceptible. Following injection with ProHeart 12, peak moxidectin blood levels will be observed approximately 7-14 days after treatment. At the end of the 12-month dosing interval, residual drug plasma concentrations are negligible. Accordingly, little or no drug accumulation is expected to occur with repeated administrations.

  6. First Shield Trio for Animal Use -

    Sep 02, 2020 · - Repels and kills ticks that may cause Lyme disease, Rocky Mountain Spotted fever, babesiosis, ehrlichiosis, bartonellosis, hepatozoonosis, and anaplasmosis - Prevents development of fleas, flea eggs, larvae and pupae for 30 days - Easy, spot-on topical application - Convenient topical treatment with patented applicator

  7. Theophylline (Oral Route) Side Effects - Mayo Clinic

    Sep 01, 2020 · pain or discomfort in the arms, jaw, back, or neck. painful urination. shakiness in the legs, arms, hands, or feet. shortness of breath. sweating. unusual tiredness or weakness. vomiting of blood or material that looks like coffee grounds. Some side effects may occur that usually do not need medical attention.

  8. Adults Coxsackie: Symptom, Treatment and Prevention | MD ...

    Sep 13, 2020 · Other treatment depends upon the symptoms (pain killers for pain, saline gargles with lukewarm water for sore throat, drugs like acetaminophen for fever, etc.). Prevention of Coxsackie in Adults. They commonly spread because of ingestion of contaminated food or water. They might also spread by respiratory droplets.

  9. Tacrolimus (Topical Route) Side Effects - Mayo Clinic
    • Incidence Not Known
    • More Common
    • Less Common
    black, tarry stools
    bloody urine
    burning or stinging sensation of the face
    general aches and pains
    Acid or sour stomach
    back pain
  10. Itraconazole (Oral Route) Side Effects - Mayo Clinic

    Sep 01, 2020 · pains in the stomach, side, or abdomen, possibly radiating to the back. Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine.

  11. Carboplatin (Intravenous Route) Side Effects - Mayo Clinic

    Sep 01, 2020 · Discuss these possible effects with your doctor. Check with your doctor as soon as possible if any of the following side effects occur: More common. Pain at place of injection Less common. Black, tarry stools blood in urine or stools cough or hoarseness, accompanied by fever or chills fever or chills